{"id":"NCT00497796","sponsor":"Shire","briefTitle":"Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients","officialTitle":"A Randomized, Double-blind Study To Assess The Efficacy And Safety Of Prophylactic Use Of Maribavir Versus Oral Ganciclovir For The Prevention Of Cytomegalovirus Disease In Recipients Of Orthotopic Liver Transplants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07-23","primaryCompletion":"2009-09-14","completion":"2009-09-14","firstPosted":"2007-07-09","resultsPosted":"2015-06-04","lastUpdate":"2021-06-11"},"enrollment":307,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Cytomegalovirus Infections"],"interventions":[{"type":"DRUG","name":"maribavir","otherNames":[]},{"type":"DRUG","name":"ganciclovir","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this research study is to investigate whether or not oral maribavir is safe and effective compared to oral ganciclovir for preventing CMV disease when administered for up to 14 weeks in patients who have had a liver transplant.","primaryOutcome":{"measure":"Number of Participants With Endpoint Committee (EC)-Confirmed Cytomegalovirus (CMV) Disease Within 6 Months Post-Transplantation","timeFrame":"6 months post-transplant","effectByArm":[{"arm":"Maribavir 100 mg BID","deltaMin":14,"sd":null},{"arm":"Ganciclovir 1000 mg TID","deltaMin":10,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":"0.2754"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":55,"countries":["United States"]},"refs":{"pmids":["39807668","38700045"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":71,"n":147},"commonTop":["Diarrhoea","Headache","Tremor","Dysgeusia","Nausea"]}}